Tetraneuron presented its E2F4‑focused AAV gene‑therapy approach aimed at upstream drivers of Alzheimer’s disease, arguing that modulating a transcription factor could prevent neurons from aberrant cell‑cycle reentry and address multiple downstream pathologies. The company, spun from José Frade’s academic work, outlined preclinical evidence and positioned TET‑101 as an upstream intervention that could impact oxidative stress, neuroinflammation and tau/amyloid cascades. Tetraneuron framed the approach as distinct from anti‑amyloid and anti‑tau strategies and said it plans to advance the program toward clinical testing pending translational milestones.